BeStock  
Stocks › Biotechnology › MNPR

Monopar Therapeutics MNPR

US equityMarket cap rank #3617Biotechnology
$69.00 −$1.29 (-1.84%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $67.35 -2.40%
Open$68.50
Prev close$70.29
Day range$67.36 – $69.86
Volume132.6K
Market cap$467.60M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$7.47M-82.5% YoY
Net profit-$6.20M-80.3% YoY
Diluted EPS-$0.72-50.0% YoY
Free cash flow-$6.17M-156.7% YoY
Operating cash flow-$6.17M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-10.9MDec '24$-2.6MMar '25$-2.5MJun '25$-3.4MSep '25$-5.2MDec '25$-3.9MMar '26$-5.3MJun '26$-6.2MSep '26

Diluted EPS by quarter

-2.75Dec '24-0.38Mar '25-0.35Jun '25-0.48Sep '25-0.64Dec '25-0.46Mar '26-0.62Jun '26-0.72Sep '26

Free cash flow by quarter

$-2.0MDec '24$-5.7MMar '25$-1.1MJun '25$-2.4MSep '25$-3.1MDec '25$-3.5MMar '26$-3.2MJun '26$-6.2MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-15.3%
Return on assets-15.0%
Return on invested capital-18.9%
Current ratio43.55
Liabilities / assets2.4%
Cash & investments$129.45M
Total debt$199,806.00
Net cash (debt)$129.25M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $7.47M $6.64M $5.23M $16.70M $6.16M
Selling and Admin Expenses $3.03M $1.88M $1.74M $6.80M $2.21M
-General & Admin Expense $3.03M $1.88M $1.74M $6.80M $2.21M
Research & Development $4.44M $4.77M $3.49M $9.90M $3.94M
Operating Profit -$7.47M -$6.64M -$5.23M -$16.70M -$6.16M
Net Non-Operating Interest Income (Expense) $1.27M $1.30M $1.33M $2.99M $954,434.00
Non-Operating Interest Income $1.27M $1.30M $1.33M $2.99M $954,434.00
Pretax Profit -$6.20M -$5.31M -$3.89M -$13.72M -$5.20M
Net Profit -$6.20M -$5.31M -$3.89M -$13.72M -$5.20M
Profit from Continuing Operations -$6.20M -$5.31M -$3.89M -$13.72M -$5.20M
Net Income to Parent Company -$6.20M -$5.31M -$3.89M -$13.72M -$5.20M
Net Income to Common Stockholders -$6.20M -$5.31M -$3.89M -$13.72M -$5.20M
Basic EPS -$0.72 -$0.62 -$0.46 -$1.85 -$0.64
Diluted EPS -$0.72 -$0.62 -$0.46 -$1.85 -$0.64
Other Income (Expense) – $32,158.00 – – –
Other Non-Operating Income (Expenses) – $32,158.00 – – –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $130.25M $134.98M $137.98M $140.72M $140.72M
Total Current Assets $129.88M $134.76M $137.74M $140.46M $140.46M
Cash and Cash Equivalents & Short-Term Investments $129.45M $134.30M $137.49M $140.40M $140.40M
-Cash and Cash Equivalents $52.63M $52.76M $52.54M $61.83M $61.83M
-Short Term Investments $76.81M $81.54M $84.95M $78.57M $78.57M
Other Current Assets $434,872.00 $464,727.00 $250,903.00 $63,745.00 $63,745.00
Total Non-Current Assets $366,718.00 $215,120.00 $239,882.00 $254,921.00 $254,921.00
Net PPE $366,718.00 $215,120.00 $239,882.00 $254,921.00 $254,921.00
-Gross PPE $366,718.00 $215,120.00 $239,882.00 $254,921.00 $254,921.00
Total Liabilities $3.18M $4.12M $2.59M $2.89M $2.89M
Total Current Liabilities $2.98M $4.02M $2.46M $2.74M $2.74M
Payables $2.98M $4.02M $2.46M $2.74M $2.74M
-Accounts Payable $2.98M $4.02M $2.46M $2.74M $2.74M
Total Non-Current Liabilities $199,806.00 $107,828.00 $131,565.00 $154,920.00 $154,920.00
Long Term Debt and Capital Lease Obligation $199,806.00 $107,829.00 $131,565.00 $154,920.00 $154,920.00
-Long Term Capital Lease Obligation $199,806.00 $107,829.00 $131,565.00 $154,920.00 $154,920.00
Total Equity $127.07M $130.85M $135.39M $137.83M $137.83M
Stockholders' Equity $127.07M $130.85M $135.39M $137.83M $137.83M
Capital Stock $6,762.00 $6,712.00 $6,699.00 $6,692.00 $6,692.00
-Common Stock $6,762.00 $6,712.00 $6,699.00 $6,692.00 $6,692.00
Additional Paid-In Capital $231.88M $229.47M $228.69M $227.20M $227.20M
Retained Earnings -$104.91M -$98.72M -$93.40M -$89.51M -$89.51M
Gains/Losses Not Affecting Retained Earnings $95,233.00 $91,317.00 $98,521.00 $131,389.00 $131,389.00
Other Non-Current Liabilities – -$1.00 – – –
Current Accrued Expenses – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$6.17M -$3.25M -$3.47M -$12.20M -$3.06M
Net cash flow from continuing operations -$6.17M -$3.25M -$3.47M -$12.20M -$3.06M
Net Income from Continuing Operations -$6.20M -$5.31M -$3.89M -$13.72M -$5.20M
Change in Working Capital -$1.29M $1.35M -$474,202.00 -$2.61M $1.42M
-Change in Payables and Accrued Expense -$1.32M $1.56M -$287,138.00 -$2.61M $1.05M
-Change in Other Current Assets $29,735.00 -$213,822.00 -$187,039.00 $15,404.00 $371,450.00
-Change In Other Working Capital $0.00 $0.00 -$25.00 -$9,432.00 -$5,002.00
Net cash flow from investing $5.46M $4.12M -$5.58M -$63.45M -$62.19M
Net Cash Flow from Continuing Investing Activities $5.46M $4.12M -$5.58M -$63.45M -$62.19M
Net Investment Purchase and Sale $5.46M $4.12M -$5.58M -$63.45M -$62.19M
Financing Cash Flow $586,232.00 -$647,389.00 -$200,203.00 $91.57M -$699,296.00
Net Cash Flow from Continuing Financing Activities $586,232.00 -$647,389.00 -$200,203.00 $91.57M -$699,296.00
Proceeds from Stock Option Exercised $884,325.00 $7,575.00 $0.00 $565,171.00 $544,800.00
Net Other Financing Charges -$298,093.00 -$654,964.00 -$200,203.00 -$1.13M -$612,710.00
Ending Cash Balance $52.63M $52.76M $52.54M $61.83M $61.83M
Net Change in Cash -$126,015.00 $220,645.00 -$9.26M $15.92M -$65.94M
Beginning Cash Balance $52.76M $52.54M $61.83M $45.82M $127.68M
Effect of Exchange Rate Changes $2,611.00 -$7,142.00 -$31,628.00 $97,266.00 $99,495.00
Free Cash Flow -$6.17M -$3.25M -$3.47M -$12.20M -$3.06M
Net Common Stock Issuance – – – $92.14M -$631,386.00

Discussion

No comments yet — be the first to weigh in on MNPR.

Sign in to join the discussion.

Scroll to Top